Tirzepatide is a novel medication primarily developed to manage type 2 diabetes but is also being explored for its potential in weight loss. It belongs to a new class of drugs known as **dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists**, which target two key hormonal pathways that regulate blood sugar levels and energy balance. By mimicking both GIP and GLP-1, tirzepatide helps stimulate insulin secretion, reduce glucagon levels, and slow down gastric emptying, leading to better blood sugar control and a reduction in food intake. This dual mechanism not only improves glycemic control but also shows significant promise in promoting weight loss, making it a potential treatment for obesity.